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Heterozygous gain-of-function (GOF) mutations in the signal transducer and
activator of transcription 1 (STAT1) have increasingly been identiﬁed as a genetic
cause of autosomal-dominant (AD) chronic mucocutaneous candidiasis (CMC). In this
article, we describe a 33-year-old man who experienced chronic refractory candidiasis,
recurrent otitis media, and pneumonia resulting in bronchiectasis, severe oral and
esophageal candidiases with strictures associated with hypothyroidism and immune
hemolytic anemia. His son also suffered from persistent candidiasis, chronic diarrhea,
poor weight gain, and pneumonia that resulted in his demise because of sepsis. The
immunological workup showed that an inverse CD4/CD8 ratio and serum immuno-
globulins were all within normal ranges. The laboratory data revealed failure in
response to Candida lymphocyte transformation test. In addition, by Sanger sequenc-
ing method, we found a heterozygous mutation, Thr385Met (T385M), located in the
DNA-binding domain of STAT1, which was previously shown to be GOF. These
ﬁndings illustrate the broad and variable clinical phenotype of heterozygous STAT1
GOF mutations. However, more clinical information and phenotype–genotype studies
are required to deﬁne the clinical phenotype caused by AD STAT1 GOF.
Keywords: gain-of-function mutations in STAT1, chronic mucocutaneous
candidiasis
Introduction
Chronic mucocutaneous candidiasis (CMC) is characterized by persistent or
recurrent Candida infections of the skin, nails, and mucosal membranes, which may
poorly respond to antifungal treatment or relapse upon discontinuation of treatment
[1]. It is often associated with a variety of infectious diseases as well as autoimmune
or endocrine disorders such as hypothyroidism [2]. CMC is frequent in immuno-
deﬁciencies affecting T cell number and/or function, associated with various
infectious and/or autoimmune manifestations [1, 2]. Patients with syndromic CMC
and primary immunodeﬁciencies have been displaying impaired interleukin (IL) 17
immunity [1]. IL-17-mediated immunity has recently been recognized as crucial in
the human mucocutaneous defense against Candida [1–6]. The mutations selec-
tively abolishing IL-17-mediated immunity are linked to pathogenesis of CMC
[4–6]. CMC is a prominent feature of autosomal-dominant (AD) hyper immuno-
globulin E (IgE) syndrome [7, 8], autosomal-recessive (AR) autoimmune
polyendocrinopathy candidiasis with ectodermal dystrophy syndrome [9–11],
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AR Caspase Recruitment Domain-containing protein 9 deﬁciency with invasive
fungal infection [12, 13], and Mendelian susceptibility to mycobacterial disease
(MSMD) with AR IL-12p40 or IL-12Rβ1 deﬁciency [7, 14, 15]. CMC can also be
found as one of the main clinical presentations or the only clinical presentation in
patients without any of the previously mentioned underlying causes of CMC disease
(CMCD) [16, 17]. AD heterozygous gain-of-function (GOF) mutations in the signal
transducer and activator of transcription 1 (STAT1) are the most common genetic
etiology of CMC disease which impaires the development of IL-17-producing T
cells [18–24]. STAT1 mutations cause a wide spectrum of diseases, ranging from
severe intracellular bacterial and viral infections (biallelic loss-of-function muta-
tions) to MSMD (monoallelic loss-of-function mutations) and CMC with other
infectious and/or autoimmune manifestations (monoallelic GOF mutations) [18, 22,
25]. Most of these mutations affect the coiled-coil domain or DNA-binding domain
(DBD) of STAT1. They increase STAT1 phosphorylation and cellular responses to
STAT1-dependant cytokines, such as interferon (IFN)-α/β, IFN-γ, IL-27, and
STAT3-dependent IL-6 and IL-21 [5, 18, 26]. In parallel, they inhibit the develop-
ment of IL-17-producing T cells [5, 18, 26, 27]. Autoimmunity probably results
from stronger IFN-α/β signaling as it is a frequent adverse effect of treatment with
recombinant IFN-α or IFN-β. In addition, some autoimmunity signs in patients
treated with IFN-α (e.g., thyroiditis) [20, 28].
Case Report
A 33-year-old male has been referred to our clinic with a history of recurrent
oral thrush and productive cough soon after the birth. He was the eighth child of
unrelated parents with seven healthy siblings. He had a history of chronic refractory
candidiasis affecting different sites of his skin, mucous membranes, and nails since
early childhood. He was diagnosed with hiatal hernia with remarkable gastroesoph-
ageal reﬂux at age of 11 months that required a surgical intervention. He also
suffered from recurrent otitis media and otorrhea since early infancy that led to
tympanomastoidectomy at the age of 12 years. Frequent episodes of pneumonia
since his childhood resulted in multiple hospitalizations with development of
clubbing, focal bronchiectasis, and partial pulmonary ﬁbrosis (Figure 1). Prophy-
lactic oral itraconazole administered with initial diagnosis of CMC at the age of
14 years resulted in partial control of oral candidiasis. He also suffered from
recurrent aphthous stomatitis, chronic diarrhea, growth retardation, and delayed
puberty. He was diagnosed with hypothyroidism at the age of 18 years and treated
with thyroid hormone replacement. At the age of 21 years, he developed severe
esophageal candidiasis with resultant strictures associated with dysphagia and
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odynophagia that led to multiple esophageal dilatations. When he was 27 years old,
he experienced multiple episodes of acute immune hemolytic anemia with warm
autoantibodies with positive Coombs’ test (Table I). High doses of prednisolone
were not tolerated by the patient; hence intravenous immunoglobulins were begun
and advised to be injected everymonth. His son also suffered from persistent whitish
oral plaques, chronic diarrhea, poor weight gain, and pneumonia since birth, which
resulted in his demise because of the sepsis at the sixth month of life. Azole-resistant
Candida albicans was isolated from his oral lesions.
Results
Flow cytometry revealed an inverse CD4/CD8 ratio and his serum
immunoglobulins were all within normal ranges (Table I). The laboratory data
showed impaired lymphocyte proliferative response to Candida and Bacillus
Calmette–Guérin antigens [impaired lymphocyte transformation test (LTT)]
(Table I). Sputum analysis and culture for acid-fast bacilli were negative. In
addition, on genetic study, we found that both of the patient and his son had a
heterozygous DBD GOF mutation at Thr385Met (T385M) in the STAT1 gene
[29] (Figures 2 and 3).
Discussion
According to previous reports, patients with STAT1 GOF mutations are
expected to have a broader immunological and infectious phenotype, given the
role of STAT1 in multiple signaling pathways [18]. Several patients with STAT1
GOF mutations possess not only CMC, but also severe viral and mycobacterial
Figure 1. Chest CT scan of the patient with GOF mutation of STAT1 focal bronchiectasis and partial
pulmonary ﬁbrosis
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infections and/or autoimmune diseases [18, 21, 24]. However, our case did not
have any problems with severe viral or mycobacterial infection. Takezaki et al.
[19] and Sharfe et al. [23] reported patients with the same T385M GOF STAT1
allele who had CMC, recurrent lower respiratory tract infections, bronchiectasis,
and autoimmunities similar to the case described here. Moreover, this case had
diaphragmatic hernia and esophageal dysmotility which seems to be a noteworthy
feature of this syndrome as hypothesized by Uzel et al. [22] and Frans et al. [30].
Table I. Laboratory results of the patient with CMC
Variable Amount Unit Normal range Comment
Immunoglobulin levels
IgG 1,022 mg/dl 767–1,590 Normal
IgA 346 mg/dl 61–356 Normal
IgM 159 mg/dl 37–286 Normal
IgE 20 IU/ml <100 Normal
Flow cytometry
CD3+ T cell 66 % 55–82 Normal
CD4+ T cell 26 % 25–75 Lower limit normal
CD8+ T cell 41 % 14–34 High
CD16+ NK cell 2.6 % 6–31 Low
CD56+ NK cell 6 % 6–31 Normal
CD19+ B cell 20 % 6–23 Normal
CD20+ B cell 19 % 6–23 Normal
Others
NBT 98 % >90% Normal
WBC 5.3 × 103 cells/μl 4.5–13.5 × 103 Normal
Hb 6.3 g/dl 12–15 Normal
PLT 199 × 103 cells/μl 140,000–440,000 Normal
Corrected retic 6.7 % 0.5–2.5 High
Neutrophil 62 % Normal
Lymphocyte 32 % Normal
Monocyte 6 % Normal




C3 84 mg/dl 90–180
C4 40 mg/dl 10–40
CH50 94 % >90%
LTT BCG <0.75 RPI 0.75–1.65 Low
LTT Candida <0.75 RPI 0.75–1.65 Low
LTT PHA 0.85 RPI 0.75–1.65 Normal
Note: NBT: nitro blue tetrazolium; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; RPI: Railway
Performance Index; CH50: total hemolytic complement; PHA: phytohemagglutinin; LTT: lymphocyte
transformation test.
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Whether the gastrointestinal manifestations are all secondary to CMC or a primary
manifestation of disturbed STAT1 signaling has yet to be determined [20, 22].
Soltész et al. [20] and Depner et al. [31] described patients carrying GOF
Figure 3. The pedigree of the family
Figure 2.Direct sequence analysis of STAT1 exon 14 in patient revealed base change of c.1153C> T
resulting in p.T385M in STAT1
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mutations of STAT1 with developed multiple intracranial aneurysms, but our
patient fortunately had no cerebral vascular complications.
Increased susceptibility to Fas activation in T385M T cells induces cell
apoptosis which might contribute to the progressive decline in T cell numbers
[23]. These ﬁndings show that some heterozygous aberrations of STAT1 can be
associated with progressive combined immunodeﬁciency, accompanied by life-
threatening severe infections. These infections increase with age, sometimes into
their second decade of life, accompanied by variable autoimmune features [23].
This ﬁnding suggests that these STAT1GOFmutations may ultimately be fatal due
to overwhelming infections [19, 23, 32, 33]. However, we discuss here a patient
with a relatively long life span.
These data suggest that heterozygous STAT1 GOF mutations underlie an
unexpectedly broad clinical phenotype. More clinical information and phenotype–
genotype studies are required to determine the clinical phenotype caused by AD
GOF mutations of STAT1.
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